Free Trial
→ Tesla pays $0 in dividends. This new fund paid $452 in one month on $5,000. (From Investors Alley) (Ad)tc pixel
NYSEAMERICAN:MYO

Myomo Q3 2026 Earnings Date & Estimates

Myomo logo
$1.24 -0.01 (-0.40%)
As of 02:58 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Myomo is estimated to report Q3 2026 earnings on Monday, November 9, 2026, after market closes. The conference call is scheduled for 4:30 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
After Market Closes
Conference Call
4:30 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Myomo in Q3 2026

Myomo is expected to post earnings of -$0.08 per share on revenue of $11.51 million. In the same quarter a year earlier Myomo reported -$0.0869 per share on revenue of $10.09 million. Myomo last reported on August 5, 2026, posting -$0.09 per share and beating the -$0.0980 consensus estimate. Myomo has beaten the consensus EPS estimate in 5 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.08
Expected Revenue
$11.51 million
Prior-Year EPS
-$0.0869
Prior-Year Revenue
$10.09 million
Expected Revenue Growth
+14.1%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.09 (Beat by +$0.0080)
Last Quarter Revenue
$11.70 million
EPS Beat Rate
5 of last 8 quarters

Prepare for the Q3 2026 Call

Myomo Q3 2026 Earnings FAQ

Myomo (NYSEAMERICAN:MYO) is estimated to report Q3 2026 earnings on Monday, November 9, 2026, after market closes. This date is estimated from past reporting schedules and may change once the company confirms it.

Myomo's Q3 2026 earnings conference call is scheduled for Monday, November 9, 2026 at 4:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Myomo to post earnings of -$0.08 per share for Q3 2026.

The consensus revenue estimate for Myomo is $11.51 million for Q3 2026.

Myomo Earnings Headlines

Myomo Names Mary-Katherine McClure as Chief Commercial Officer
October 12, 2026  |  marketscreener.comM
Myomo Appoints Mary-Katherine McClure as Chief Commercial Officer
October 12, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20261012506126/en/myomo-appoints-mary-katherine-mcclure-as-chief-commercial-officer/
Elon Musk about to bankrupt Amazon, Microsoft & Google?
Jeff Brown, the former tech executive who called the rise of Bitcoin, Tesla, and Nvidia years early, is tracking a new Elon Musk project he calls the most epic AI initiative in history. The plan could give Musk access to 50 times more computing power than the rest of the world combined, a development Brown says is drawing attention from executives at Amazon, Microsoft, and Google. Brown compares the scale of this project to the SpaceX IPO, which minted thousands of millionaires overnight.tc pixel
November 2 at 1:00 AM  |  Brownstone Research (Ad)
Myomo (MYO) Stock Forecast & Price Target
September 4, 2026  |  investing.comhttps://www.investing.com/equities/myomo-inc-consensus-estimates
Myomo to Present at the H.C. Wainwright 28th Annual Global Investment Conference
September 1, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/myomo-present-h-c-wainwright-200500266.html
Myomo (MYO) Receives a Rating Update from a Top Analyst
August 15, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/MYO/pressreleases/3719785/myomo-myo-receives-a-rating-update-from-a-top-analyst/
See More Myomo Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Myomo? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Myomo and other key companies, straight to your email.

About Myomo

Myomo (NYSEAMERICAN:MYO) is a medical device company that develops and markets wearable robotic braces designed to help individuals with impaired upper-limb function regain movement and perform activities of daily living. Its principal product is the MyoPro, a lightweight, electrically powered orthosis that detects a user’s residual muscle signals and assists movement of the arm and hand.

The MyoPro is intended for people affected by neuromuscular disorders and injuries, including stroke, brachial plexus injury, multiple sclerosis, traumatic brain injury and spinal cord injury. The device is designed to support functional arm and hand movement rather than replace the user’s own muscles, and may be provided through medical providers, rehabilitation specialists and other distribution channels.

Founded in 2004, Myomo is headquartered in Boston, Massachusetts, and serves customers in the United States and international markets. The company combines medical-device engineering, rehabilitation technology and patient support services in its efforts to expand access to powered orthotic solutions.

View Myomo Profile
Earnings Tools